세계의 아세트아미노펜 오피오이드 배합제 시장 보고서(2025년)

Acetaminophen-Opioid Combination Global Market Report 2025

US $ 4,490 ￦ 6,272,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,065,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,859,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

아세트아미노펜 오피오이드 배합제 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 5.1%로 성장할 전망이며, 38억 8,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 다제 병용에 의한 통증관리에 대한 의식 고조, 비침습적 및 경구적 통증 치료에 대한 수요 고조, 개별화 의료 및 맞춤형 통증 치료에 대한 중시 고조, 남용 억제 제제(ADF)에 대한 투자 증가, 암과 정형외과 질환의 세계 증가 등에 기인할 것으로 보입니다. 이 기간에 예상되는 주요 동향에는 ADF 기술의 진보, 전자 진료기록카드(EHR) 및 배합 모니터링 프로그램(PMP)의 통합, 기술을 구사한 원격 통증 관리 툴의 채택, 서방성 약물 전달 시스템의 혁신, 약리유전체학과 개별화 치료 접근법의 진보 등이 있습니다.

만성 통증의 유병률 증가는 향후 수년간 아세트아미노펜 오피오이드 배합제 시장의 성장을 이끌 것으로 예측됩니다. 만성 통증은 3-6개월 이상 지속되는 지속성 또는 반복성 통증으로 정의되며, 전형적인 회복 기간을 넘어 지속되며, 많은 경우 개인의 일상생활 및 행복감에 큰 영향을 미칩니다. 이러한 통증의 증가는 앉아서 생활하는 스타일이 주요 원인입니다. 앉아 있는 생활 스타일은 나쁜 자세와 근력 저하를 초래하여 신체에 추가적인 부담을 주고 장기적인 통증을 유발합니다. 아세트아미노펜 오피오이드 배합제는 여러 동통 경로에 동시에 작용함으로써 효과적인 완화를 가져오고, 동통 관리를 개선하며, 일상생활 기능을 향상시키고, 필요한 오피오이드 투여량을 줄일 수 있습니다. 예를 들면, 2024년 6월, 호주 보건 복지 랩(Australian Institute of Health and Welfare)은, 2023년에 있어서의 만성 질환에 의해서 오스트레일리아인의 건강 수명은 약 440만 년 상실되며, 이는 국가의 질병 부담 전체의 85%에 상당한다고 보고했습니다. 그 결과 만성 통증의 증가가 아세트아미노펜 오피오이드 배합제 시장 확대에 박차를 가하고 있습니다.

정형외과 수술 건수 증가가 향후 수년간 아세트아미노펜 오피오이드 배합제 시장의 성장을 가속할 것으로 예측됩니다. 정형외과 수술은 근골격계 뼈, 관절, 근육, 인대에 영향을 미치는 상태를 진단, 치료, 복구하는 처치를 포함합니다. 고령화 사회가 더 많은 퇴행성 근골격계 장애에 직면하고, 가동성을 회복시키고 통증을 경감시키는 개입의 필요성이 높아짐에 따라 이러한 수술에 대한 수요는 증가하고 있습니다. 아세트아미노펜과 오피오이드의 병용은 여러 동통 경로를 표적으로 하는 것으로, 정형외과 수술 후 중등도에서 심한 수술 후 동통 관리에 효과적입니다. 이 접근 방식은 환자의 쾌적성 및 가동성을 개선하는 동시에 오피오이드의 고용량 투여 필요성을 줄일 수 있습니다. 예를 들어 2023년 9월 미국 헬스케어 기술 기업인 Curvo Labs Inc.는 미국에서 인공 슬관절 치환술 건수가 2021년 123만 5835건에서 2022년 129만 9084건으로 증가했다고 보고했습니다. 이처럼 정형외과 수술 건수 증가가 아세트아미노펜 오피오이드 배합제 시장 확대에 박차를 가하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

• 세계의 아세트아미노펜 오피오이드 배합제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 아세트아미노펜 오피오이드 배합제 시장 : 성장률 분석
• 세계의 아세트아미노펜 오피오이드 배합제 시장 실적 : 규모 및 성장(2019-2024년)
• 세계의 아세트아미노펜 오피오이드 배합제 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
• 세계의 아세트아미노펜 오피오이드 배합제 : 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 아세트아미노펜 오피오이드 배합제 시장 : 제품별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 하이드로코돈 아세트아미노펜
• 옥시코돈 아세트아미노펜
• 코데인 아세트아미노펜
• 트라마돌 아세트아미노펜
• 기타
• 세계의 아세트아미노펜 오피오이드 배합제 시장 : 강도 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 저용량 조합
• 중용량에서 고용량의 조합
• 서방형 배합제
• 세계의 아세트아미노펜 오피오이드 배합제 시장 : 적응증별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 급성 통증
• 만성 통증
• 세계의 아세트아미노펜 오피오이드 배합제 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 약국
• 소매 약국
• 온라인 약국
• 클리닉
• 세계의 아세트아미노펜 오피오이드 배합제 시장 : 하이드로코돈 아세트아미노펜별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 즉시 릴리스(IR)
• 서방형(ER)
• 복용량 강도
• 배합
• 세계의 아세트아미노펜 오피오이드 배합제 시장 : 옥시코돈 아세트아미노펜별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 즉시 릴리스(IR)
• 서방형(ER)
• 복용량 강도
• 배합
• 세계의 아세트아미노펜 오피오이드 배합제 시장 : 코데인 아세트아미노펜별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 즉시 릴리스(IR)
• 복용량 강도
• 배합
• 세계의 아세트아미노펜 오피오이드 배합제 시장 : 트라마돌 아세트아미노펜의별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 즉시 릴리스(IR)
• 복용량 강도
• 배합
• 세계의 아세트아미노펜 오피오이드 배합제 시장 : 기타 제품별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 기타 오피오이드 아세트아미노펜 배합
• 배합
• 강도 변화

제7장 지역별 및 국가별 분석

• 세계의 아세트아미노펜 오피오이드 배합제 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 아세트아미노펜 오피오이드 배합제 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

• 아세트아미노펜 오피오이드 배합제 시장 : 경쟁 구도
• 아세트아미노펜 오피오이드 배합제 시장 : 기업 프로파일
  • Bayer AG
  • Abbott Laboratories
  • GlaxoSmithKline plc(GSK)
  • Sun Pharmaceutical Industries Ltd
  • Endo Pharmaceuticals

제31장 기타 주요 기업 및 혁신 기업

• Amneal Pharmaceuticals
• Mallinckrodt Pharmaceuticals plc
• Lupin Pharmaceuticals
• Granules Pharmaceuticals Inc.
• Alvogen
• Camber Pharmaceuticals Inc.
• Watson Laboratories
• Genus Lifesciences Inc.
• Elite Pharmaceuticals Inc.
• Healthkind Labs Pvt Ltd
• Eraas International
• Boca Pharmacal Inc.
• Taj Life Sciences Pvt. Ltd.
• West-Ward Pharmaceuticals Corp.
• Divine savior pvt. ltd.

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

• 아세트아미노펜 오피오이드 배합제 시장(2029년) : 새로운 기회를 제공하는 국가
• 아세트아미노펜 오피오이드 배합제 시장(2029년) : 새로운 기회를 제공하는 부문
• 아세트아미노펜 오피오이드 배합제 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제36장 부록

AJY

영문 목차

영문목차

An acetaminophen-opioid combination is a prescribed medication that combines acetaminophen, a non-opioid analgesic and antipyretic, with an opioid pain reliever to provide enhanced pain management. Its use is strictly regulated due to potential risks, including opioid dependency and liver toxicity associated with high doses of acetaminophen.

The primary types of acetaminophen-opioid combinations include hydrocodone-acetaminophen, oxycodone-acetaminophen, codeine-acetaminophen, tramadol-acetaminophen, and others. Hydrocodone-acetaminophen is a prescription medication used for severe pain that merges an opioid and non-opioid component, with risks such as addiction, liver damage, and respiratory depression. It is offered in various formulations, including low-dose, moderate- to high-dose, and extended-release combinations, for multiple indications like acute and chronic pain. These products are distributed through several channels, including hospital pharmacies, retail pharmacies, online pharmacies, and clinics.

The acetaminophen-opioid combinations market research report is one of a series of new reports from The Business Research Company that provides acetaminophen-opioid combinations market statistics, including the acetaminophen-opioid combinations industry global market size, regional shares, competitors with the acetaminophen-opioid combinations market share, detailed acetaminophen-opioid combinations market segments, market trends, opportunities, and any further data you may need to thrive in the acetaminophen-opioid combinations industry. This acetaminophen-opioid combinations market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acetaminophen-opioid combination market size has grown strongly in recent years. It will grow from $3.02 billion in 2024 to $3.18 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. Growth during the historic period can be attributed to the rising prevalence of moderate to severe pain conditions, increased reliance on combination analgesics, a growing number of surgical procedures, an expanding geriatric population, and the development of pharmaceutical sales infrastructure in emerging markets

The acetaminophen-opioid combination market size is expected to see strong growth in the next few years. It will grow to $3.88 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. Growth in the forecast period can be attributed to increasing awareness of multimodal pain management, rising demand for non-invasive and oral pain therapies, a growing emphasis on personalized medicine and customized pain treatments, increased investment in abuse-deterrent formulations (ADF), and the global rise in cancer and orthopedic disorders. Key trends expected during this period include progress in ADF technologies, integration of electronic health records (EHR) with prescription monitoring programs (PMPs), adoption of technology-enabled remote pain management tools, innovations in extended-release drug delivery systems, and advancements in pharmacogenomics and personalized treatment approaches.

The increasing prevalence of chronic pain is expected to drive the growth of the acetaminophen-opioid combination market in the coming years. Chronic pain is defined as persistent or recurring pain lasting longer than three to six months, extending beyond the typical recovery period, and often significantly impacting an individual's daily life and well-being. This rise is largely due to sedentary lifestyles, which lead to poor posture and weakened muscles, placing additional strain on the body and contributing to long-term pain. Acetaminophen-opioid combinations offer effective relief by simultaneously addressing multiple pain pathways, improving pain management, enhancing daily functionality, and potentially reducing the required opioid dosage. For example, in June 2024, the Australian Institute of Health and Welfare reported that chronic conditions in 2023 led Australians to lose around 4.4 million years of healthy life, representing 85% of the nation's total disease burden. As a result, the growing incidence of chronic pain is fueling the expansion of the acetaminophen-opioid combination market.

The rising number of orthopedic surgical procedures is expected to drive the growth of the acetaminophen-opioid combination market in the coming years. Orthopedic surgeries involve procedures that diagnose, treat, or repair conditions affecting the bones, joints, muscles, and ligaments of the musculoskeletal system. The demand for these surgeries is increasing as the aging population faces more degenerative musculoskeletal disorders, leading to a greater need for interventions that restore mobility and reduce pain. Acetaminophen-opioid combinations are effective in managing moderate to severe postoperative pain following orthopedic surgeries by targeting multiple pain pathways. This approach improves patient comfort and mobility while potentially reducing the need for higher opioid dosages. For example, in September 2023, Curvo Labs, Inc., a US-based healthcare technology firm, reported that the number of knee replacement surgeries in the U.S. rose from 1,235,835 in 2021 to 1,299,084 in 2022. Thus, the growing number of orthopedic surgical procedures is fueling the expansion of the acetaminophen-opioid combination market.

Major companies in the acetaminophen-opioid combination market are concentrating on developing advanced products, such as oxycodone hydrochloride and acetaminophen tablets, to improve pain relief effectiveness while minimizing the risk of opioid dependence. These tablets combine a potent opioid analgesic with a non-opioid pain reliever to address moderate to severe pain through dual-action mechanisms that work via complementary pathways. For example, in May 2025, Elite Pharmaceuticals, Inc., a US-based specialty pharmaceutical company, introduced its generic version of Percocet in 5mg/325mg, 7.5mg/325mg, and 10mg/325mg strengths. Manufactured under current Good Manufacturing Practice (cGMP) standards, this product offers a reliable, high-quality alternative to branded Percocet and addresses immediate-release pain management needs. It is approved for the treatment of moderate to moderately severe pain and represents a notable entry for Elite into the targeted generic pharmaceutical market.

Major players in the acetaminophen-opioid combination market are Bayer AG, Abbott Laboratories, GlaxoSmithKline plc (GSK), Sun Pharmaceutical Industries Ltd, Endo Pharmaceuticals, Amneal Pharmaceuticals, Mallinckrodt Pharmaceuticals plc, Lupin Pharmaceuticals, Granules Pharmaceuticals Inc., Alvogen, Camber Pharmaceuticals Inc., Watson Laboratories, Genus Lifesciences Inc., Elite Pharmaceuticals Inc., Healthkind Labs Pvt Ltd, Eraas International, Boca Pharmacal Inc., Taj Life Sciences Pvt. Ltd., West-Ward Pharmaceuticals Corp., Divine savior pvt. ltd.

North America was the largest region in the acetaminophen-opioid combination market in 2024. The regions covered in acetaminophen-opioid combination report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acetaminophen-opioid combination market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acetaminophen-opioid combination market consists of sales of pentazocine and acetaminophen, meperidine and acetaminophen and tapentadol and acetaminophen. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acetaminophen-Opioid Combination Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acetaminophen-opioid combination market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acetaminophen-opioid combination ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acetaminophen-opioid combination market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Hydrocodone-Acetaminophen; Oxycodone-Acetaminophen; Codeine-Acetaminophen; Tramadol-Acetaminophen; Other Products
• 2) By Strength: Low Dose Combinations; Moderate To High Dose Combinations; Extended-Release Combinations
• 3) By Indication: Acute Pain; Chronic Pain
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Clinics
• Subsegments:
• 1) By Hydrocodone-Acetaminophen: Immediate Release (IR); Extended Release (ER); Dosage Strength; Formulation
• 2) By Oxycodone-Acetaminophen: Immediate Release (IR); Extended Release (ER); Dosage Strength; Formulation
• 3) By Codeine-Acetaminophen: Immediate Release (IR); Dosage Strength; Formulation
• 4) By Tramadol-Acetaminophen: Immediate Release (IR); Dosage Strength; Formulation
• 5) By Other Products: Other Opioid-Acetaminophen Combinations; Dosage Forms; Strength Variants
• Companies Mentioned: Bayer AG; Abbott Laboratories; GlaxoSmithKline plc (GSK); Sun Pharmaceutical Industries Ltd; Endo Pharmaceuticals
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acetaminophen-Opioid Combination Market Characteristics

3. Acetaminophen-Opioid Combination Market Trends And Strategies

4. Acetaminophen-Opioid Combination Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Acetaminophen-Opioid Combination Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acetaminophen-Opioid Combination PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acetaminophen-Opioid Combination Market Growth Rate Analysis
• 5.4. Global Acetaminophen-Opioid Combination Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acetaminophen-Opioid Combination Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acetaminophen-Opioid Combination Total Addressable Market (TAM)

6. Acetaminophen-Opioid Combination Market Segmentation

• 6.1. Global Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hydrocodone-Acetaminophen
• Oxycodone-Acetaminophen
• Codeine-Acetaminophen
• Tramadol-Acetaminophen
• Other Products
• 6.2. Global Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Low Dose Combinations
• Moderate To High Dose Combinations
• Extended-Release Combinations
• 6.3. Global Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Pain
• Chronic Pain
• 6.4. Global Acetaminophen-Opioid Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Clinics
• 6.5. Global Acetaminophen-Opioid Combination Market, Sub-Segmentation Of Hydrocodone-Acetaminophen, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immediate Release (IR)
• Extended Release (ER)
• Dosage Strength
• Formulation
• 6.6. Global Acetaminophen-Opioid Combination Market, Sub-Segmentation Of Oxycodone-Acetaminophen, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immediate Release (IR)
• Extended Release (ER)
• Dosage Strength
• Formulation
• 6.7. Global Acetaminophen-Opioid Combination Market, Sub-Segmentation Of Codeine-Acetaminophen, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immediate Release (IR)
• Dosage Strength
• Formulation
• 6.8. Global Acetaminophen-Opioid Combination Market, Sub-Segmentation Of Tramadol-Acetaminophen, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immediate Release (IR)
• Dosage Strength
• Formulation
• 6.9. Global Acetaminophen-Opioid Combination Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Other Opioid-Acetaminophen Combinations
• Dosage Forms
• Strength Variants

7. Acetaminophen-Opioid Combination Market Regional And Country Analysis

• 7.1. Global Acetaminophen-Opioid Combination Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acetaminophen-Opioid Combination Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acetaminophen-Opioid Combination Market

• 8.1. Asia-Pacific Acetaminophen-Opioid Combination Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acetaminophen-Opioid Combination Market

• 9.1. China Acetaminophen-Opioid Combination Market Overview
• 9.2. China Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acetaminophen-Opioid Combination Market

• 10.1. India Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acetaminophen-Opioid Combination Market

• 11.1. Japan Acetaminophen-Opioid Combination Market Overview
• 11.2. Japan Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acetaminophen-Opioid Combination Market

• 12.1. Australia Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acetaminophen-Opioid Combination Market

• 13.1. Indonesia Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acetaminophen-Opioid Combination Market

• 14.1. South Korea Acetaminophen-Opioid Combination Market Overview
• 14.2. South Korea Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acetaminophen-Opioid Combination Market

• 15.1. Western Europe Acetaminophen-Opioid Combination Market Overview
• 15.2. Western Europe Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acetaminophen-Opioid Combination Market

• 16.1. UK Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acetaminophen-Opioid Combination Market

• 17.1. Germany Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acetaminophen-Opioid Combination Market

• 18.1. France Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acetaminophen-Opioid Combination Market

• 19.1. Italy Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acetaminophen-Opioid Combination Market

• 20.1. Spain Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acetaminophen-Opioid Combination Market

• 21.1. Eastern Europe Acetaminophen-Opioid Combination Market Overview
• 21.2. Eastern Europe Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acetaminophen-Opioid Combination Market

• 22.1. Russia Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acetaminophen-Opioid Combination Market

• 23.1. North America Acetaminophen-Opioid Combination Market Overview
• 23.2. North America Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acetaminophen-Opioid Combination Market

• 24.1. USA Acetaminophen-Opioid Combination Market Overview
• 24.2. USA Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acetaminophen-Opioid Combination Market

• 25.1. Canada Acetaminophen-Opioid Combination Market Overview
• 25.2. Canada Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acetaminophen-Opioid Combination Market

• 26.1. South America Acetaminophen-Opioid Combination Market Overview
• 26.2. South America Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acetaminophen-Opioid Combination Market

• 27.1. Brazil Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acetaminophen-Opioid Combination Market

• 28.1. Middle East Acetaminophen-Opioid Combination Market Overview
• 28.2. Middle East Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acetaminophen-Opioid Combination Market

• 29.1. Africa Acetaminophen-Opioid Combination Market Overview
• 29.2. Africa Acetaminophen-Opioid Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acetaminophen-Opioid Combination Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acetaminophen-Opioid Combination Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acetaminophen-Opioid Combination Market Competitive Landscape And Company Profiles

• 30.1. Acetaminophen-Opioid Combination Market Competitive Landscape
• 30.2. Acetaminophen-Opioid Combination Market Company Profiles
  • 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline plc (GSK) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sun Pharmaceutical Industries Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Endo Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis

31. Acetaminophen-Opioid Combination Market Other Major And Innovative Companies

• 31.1. Amneal Pharmaceuticals
• 31.2. Mallinckrodt Pharmaceuticals plc
• 31.3. Lupin Pharmaceuticals
• 31.4. Granules Pharmaceuticals Inc.
• 31.5. Alvogen
• 31.6. Camber Pharmaceuticals Inc.
• 31.7. Watson Laboratories
• 31.8. Genus Lifesciences Inc.
• 31.9. Elite Pharmaceuticals Inc.
• 31.10. Healthkind Labs Pvt Ltd
• 31.11. Eraas International
• 31.12. Boca Pharmacal Inc.
• 31.13. Taj Life Sciences Pvt. Ltd.
• 31.14. West-Ward Pharmaceuticals Corp.
• 31.15. Divine savior pvt. ltd.

32. Global Acetaminophen-Opioid Combination Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acetaminophen-Opioid Combination Market

34. Recent Developments In The Acetaminophen-Opioid Combination Market

35. Acetaminophen-Opioid Combination Market High Potential Countries, Segments and Strategies

• 35.1 Acetaminophen-Opioid Combination Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acetaminophen-Opioid Combination Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acetaminophen-Opioid Combination Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료